Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Reduce” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received an average rating of “Reduce” from the seven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company.

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock opened at $5.13 on Monday. Bayer Aktiengesellschaft has a 52-week low of $4.94 and a 52-week high of $9.79. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. The firm has a fifty day moving average of $6.78 and a 200-day moving average of $7.22.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The business had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. On average, equities research analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.